安諾其(300067.SZ):4.5億元定增方案被深交所問詢
格隆匯8月3日丨安諾其(300067.SZ)公佈,公司於2020年8月2日收到深交所出具的《關於上海安諾其集團股份有限公司申請向特定對象發行股票的審核問詢函》(審核函〔2020〕020092號),深交所發行上市審核機構對公司提交的向特定對象發行股票申請文件進行了審核,並形成了審核問詢問題。
據悉,2020年6月30日盤後,安諾其披露2020年度非公開發行股票預案(修訂稿),此次非公開發行股票募集資金總額不超過4.5億元,其中2.5億元用於22750噸染料及中間體項目,0.4億元用於年產5000噸數碼墨水項目,0.7億元用於年產10000噸廣譜消毒劑單過硫酸氫鉀複合鹽項目,及0.9億元用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.